Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

[ASTRAZENECA] Dia da Asma: pandemia da Covid-19 reforça a importância do controle da doença que acomete a 20 milhões de brasileiros

Informação precisa e acompanhamento médico personalizado são essenciais para que o paciente reconheça os sintomas, gatilhos do ambiente e quando há uma crise de asma


News provided by

AstraZeneca Brasil

May 04, 2021, 15:08 ET

Share this article

Share toX

Share this article

Share toX

SÃO PAULO, 4 de maio de 2021 /PRNewswire/ -- Organizado pela Iniciativa Global Contra a Asma (Global Initiative for Asthma - GINA, em inglês), a primeira terça-feira do mês de maio destaca uma das doenças crônicas mais comuns entre os brasileiros, cujo controle se torna ainda mais relevante para mais de 20 milhões de pessoas no paísi, dado o cenário de pandemia da COVID-19. Segundo estimativas da Organização Mundial da Saúde (OMS)ii, mais de 339 milhões de pessoas tem asma em todo o mundo e com registro de 417.918 mortes devido à doença - dados globais de 2016.

A asma se caracteriza pela inflamação e o estreitamento dos brônquios, que limita a passagem do ar e dificulta o processo respiratório. Sua causa exata não é conhecidaiii, porém alguns fatores ambientais e genéticos podem ser considerados gatilhos da asma, como a exposição à poeira, ácaros, fungos, variações climáticas, além de infecções virais - como o novo coronavírus.

"É importante que o tratamento da asma seja personalizado buscando um melhor controle da doença e atendendo a necessidade de cada paciente. A pandemia enfatizou a importância da educação sobre nossa condição de saúde e, por isso, sabemos que um paciente com melhor entendimento sobre sua doença, conhece melhor os sintomas, fatores desencadeantes e/ou irritantes e, também, sabe reconhecer quando há uma crise de asma, seguindo as recomendações de seu médico", explica Márcio Ferreira Penha, TA Head do departamento Respiratória e Imunologia da AstraZeneca Brasil.

Segundo a Sociedade Brasileira de Pneumologia e Tisiologia (SBPT) iv, por tratar-se de um vírus respiratório, o novo coronavírus traz um potencial risco de exacerbação e piores desfechos da asma e da própria COVID-19 em pacientes com a doença não controlada, ou seja, com o tratamento de manutenção inadequado. Dado que grande parte da população não é asmática e não sabe como reconhecer uma crise de asma, a conscientização e a orientação médica são essenciais. Por isso, cada caso deve ser analisado junto ao médico especialista, baseando-se nas melhores evidências científicas disponíveis até o momento - assim como orienta a SBPT.

Outro ponto a ser considerado é a existência de diferentes tipos de asma, fato que pode dificultar o diagnóstico preciso. Um pesquisav revelou que 82% dos asmáticos demoram cerca de 5 anos para obter o diagnóstico correto e que 74% foi diagnosticado com algum tipo de bronquite, o que acaba minimizando o tratamento.

"Sabemos que asma não tem cura, mas há tratamentos que controlam a doença e que podem oferecer bem-estar e melhora na qualidade de vida do paciente. Na situação de pandemia em que vivemos, é ainda mais importante que pacientes com doenças respiratórias crônicas, como a asma, sigam seus tratamentos como recomendado e mantenham sua asma controlada, evitando assim, crises e a piora de seus quadros clínicos. Queremos uma população saudável e ativa, que tenha informações adequadas para se cuidar e enfrentar um cenário de pandemia da melhor maneira possível", ressalta Márcio Ferreira Penha, TA Head do departamento Respiratória e Imunologia da AstraZeneca Brasil.

Sobre a AstraZeneca  
A AstraZeneca é uma empresa biofarmacêutica, voltada para inovação e com foco principal na descoberta, desenvolvimento e comercialização de medicamentos de prescrição, principalmente para o tratamento de doenças em quatro principais linhas terapêuticas - Oncologia, Doenças Cardiovasculares, Renais & Metabólicas e Respiratória. A companhia também atua nas áreas de autoimunidade e neurociência. A AstraZeneca está presente em mais de 100 países e seus medicamentos inovadores são usados por milhões de pacientes em todo o mundo. Para mais informações acesse: www.astrazeneca.com.br 

Referências
____________

i Biblioteca Virtual em Saúde / Ministério da Saúde: https://bvsms.saude.gov.br/ultimas-noticias/3212-21-6-dia-nacional-de-controle-da-asma-2
ii World Health Report / World Health Organization – 2018: http://www.who.int/respiratory/asthma/en/ 
iii Sociedade Brasileira de Pneumologia e Tisiologia: https://sbpt.org.br/portal/publico-geral/doencas/asma-perguntas-e-respostas/ 
iv SBPT - Orientações sobre asma durante a pandemia da Covid-19: https://sbpt.org.br/portal/wp-content/uploads/2021/02/Asma-COVID-19-AMB-SBPT-ASBAI.pdf
v Pesquisa Abril Inteligência e AstraZeneca - "A asma na visão e na vida dos brasileiros" - out/nov-2018: https://pfarma.com.br/coronavirus/5634-asma-covid19.html 
Associação Brasileira de Asmáticos - São Paulo: http://www.abrasaopaulo.org/perguntas.asp
Dr. Drauzio Varella: https://drauziovarella.uol.com.br/doencas-e-sintomas/asma/ 
GINA no Brasil: https://www.ginanobrasil.org.br/mortes-por-asma-2016/ 
Pesquisa Nacional de Saúde (PNS) / Ministério da Saúde / Instituto Brasileiro de Geografia e Estatística (IBGE): https://www.pns.icict.fiocruz.br/
Programa FazBem: https://blog.programafazbem.com.br/post/conheca-o-conectar#:~:text=Mas%20o%20que%20%C3%A9%20esse,sobre%20a%20import%C3%A2ncia%20do%20tratamento 
Sociedade Brasileira de Medicina de Família e Comunidade – SBMFC: https://www.sbmfc.org.br/noticias/dia-mundial-de-combate-a-asma-5-de-maio-de-2020/ 
The Global Initiative for Asthma (GINA): https://ginasthma.org/about-us/

Material destinado a todos os públicos. Produzido em maio/2021. BR-12674

FONTE AstraZeneca Brasil

Related Links

http://www.astrazeneca.com.br

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.